Table 2.
Patients by Protocol in Each Analyzed Subgroup
| Group | No. of Patients in Subgroup (%) | Total No. of Protocol Patients | ||||
|---|---|---|---|---|---|---|
| CNS3 | T-Cell, WBC > 100 × 109/L | B-Cell, WBC > 100 × 109/L | T Cell, Slow Early Response | B Cell, Slow Early Response | ||
| AIEOP | 44 (2.2) | 100 (5.0) | 100 (5.0) | 79 (4.0) | 128 (6.4) | 1,999 |
| BFM | 110 (3.1) | 184 (5.1) | 179 (5.0) | 179 (5.0) | 172 (4.8) | 3,582 |
| COALL | 18 (2.0) | 47 (5.2) | 48 (5.3) | 52 (5.7) | 226 (24.8) | 910 |
| COG | 67 (2.1) | 144 (4.5) | NA* | 55 (1.7) | NA* | 3,182 |
| DCOG | 21 (2.4) | 47 (5.5) | 57 (6.6) | NA | NA | 859 |
| JACLS | 41 (3.3) | 39 (3.1) | 64 (5.1) | 40 (3.2) | 80 (6.4) | 1,246 |
| NOPHO | 31 (2.9) | 64 (5.9) | 61 (5.6) | 13 (1.2) | 51 (4.7) | 1,082 |
| SJCRH | 8 (1.6) | 34 (7.0) | 26 (5.3) | 21 (4.3) | 68 (13.9) | 488 |
| UK | 49 (1.8) | 167 (6.0) | 168 (6.0) | 80 (2.9) | 227 (8.2) | 2,783 |
| DFCI | 17 (3.5) | 18 (3.7) | 32 (6.5) | NA | NA | 492 |
Abbreviations: AIEOP, Associazione Italiana Ematologia ed Oncologia Pediatrica; BFM, Berlin-Frankfurt-Münster; COALL, Cooperative Acute Lymphoblastic Leukemia Group; COG, Children’s Oncology Group; CNS3, overt CNS involvement; DCOG, Dutch Children’s Oncology Group; DFCI, Dana-Farber Cancer Institute; JACLS, Japanese Childhood Leukemia Study Group; NA, not available; NOPHO, Nordic Pediatric Hematology and Oncology Study Group; POG, Pediatric Oncology Group; SJCRH, St Jude Children’s Research Hospital; UK, United Kingdom and Ireland Group.
*
POG 9900 was not included in subgroup analysis because postinduction therapy details were not available.